Request Demo
Recent blog posts
Latest Hotspot
3 min read
UK's MHRA approves CRISPR and Vertex's gene-editing treatment, CASGEVY, for Sickle Cell and Beta Thalassemia using CRISPR/Cas9
23 November 2023
CRISPR Therapeutics and Vertex received approval from the UK's MHRA for the initial gene-edited treatment, CASGEVY™ (exagamglogene autotemcel), targeting Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia employing CRISPR/Cas9 technology.
Latest Hotspot
3 min read
Carmot Therapeutics starts phase 2 trial for CT-868, a GLP-1/GIP agonist, to treat Type 1 Diabetes
23 November 2023
Carmot Therapeutics has initiated a phase 2 clinical study on CT-868, a unique dual GLP-1/GIP receptor agonist, to treat Type 1 Diabetes.
Latest Hotspot
3 min read
Repare Therapeutics launches two clinical trials by 2024: RP-1664 and RP-3467, both oral inhibitors
23 November 2023
Repare Therapeutics introduces two initiatives set to commence clinical testing by 2024: oral PLK4 inhibitor RP-1664, and oral Polθ inhibitor RP-3467.
Latest Hotspot
3 min read
JAMP Pharma and Alvotech have been approved to sell Jamteki (AVT04), the first biosimilar of Stelara® (ustekinumab)
23 November 2023
Alvotech, a global biotech firm specializing in biosimilar drugs, and Canada's JAMP Pharma have announced Health Canada's approval for AVT04, a Stelara® biosimilar. It will be marketed as Jamteki™.
Latest Hotspot
3 min read
Kyverna Therapeutics announces Phase 2 trial approval for KYV-101, a full human CD19 CAR T-Cell therapy for Myasthenia Gravis, by the FDA
22 November 2023
Kyverna Therapeutics reveals FDA approval for Phase 2 study of KYV-101, a complete human CD19 CAR T-Cell treatment for Myasthenia Gravis.
Latest Hotspot
3 min read
Latest updates on PACIFIC-2 Phase III trial studying Imfinzi with chemo and radiation for inoperable Stage III non-small cell lung cancer
22 November 2023
Latest news on PACIFIC-2 Phase III study of Imfinzi given along with platinum-based chemo and radiotherapy for Stage III non-small cell lung cancer that can't be surgically removed.
Latest Hotspot
3 min read
Mozart Therapeutics presents MTX-101 trial outcomes, a dual-action CD8 Treg modifier for autoimmune treatment, at 2023 ACR Convergence
22 November 2023
Mozart Therapeutics shares trial results for MTX-101, a unique dual-action CD8 Treg adjuster used for treating autoimmune diseases, at the 2023 American College of Rheumatology Convergence.
Latest Hotspot
3 min read
SCG Cell Therapy finds that SCG101 boosts tumor response and sustains antiviral effects in advanced liver cancer patients with HBV
22 November 2023
SCG Cell Therapy reports that SCG101 enhances tumor reactions and maintains consistent antiviral actions in patients having advanced hepatocellular carcinoma linked to HBV.
Latest Hotspot
3 min read
Ionetix will supply Bayer with Actinium-225 (Ac-225), a therapeutic radioisotope
22 November 2023
Ionetix Corporation has publicized that it has entered into a supply contract for the therapeutic radioisotope actinium-225 (Ac-225) with Bayer.
Latest Hotspot
3 min read
Alpine Immune Sciences reveals new study results for Lupus treatment at 2023 Rheumatology Convergence
22 November 2023
Alpine Immune Sciences unveils fresh Acazicolcept study results for Systemic Lupus Erythematosus at 2023 Rheumatology Convergence by American College.
Latest Hotspot
3 min read
NImmune Biopharma released promising Phase 2 results for their lupus drug NIM-1324 at the 2023 ACR Convergence
20 November 2023
NImmune Biopharma unveiled promising early human trial results for NIM-1324, a Phase 2 drug candidate for Systemic Lupus Erythematosus, at the 2023 American College of Rheumatology Convergence.
Latest Hotspot
3 min read
Novo Nordisk unveils Wegovy® cardiac outcomes at AHA meeting and in NEJM
20 November 2023
Novo Nordisk presents cardiovascular results for Wegovy® (Semaglutide 2.4 mg) at the American Heart Association's scientific conference, also concurrently published in the New England Journal of Medicine.